Relay Therapeutics (NASDAQ:RLAY) Insider Sells $954,500.00 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Peter Rahmer sold 50,000 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $19.09, for a total value of $954,500.00. Following the completion of the transaction, the insider directly owned 225,857 shares of the company’s stock, valued at approximately $4,311,610.13. The trade was a 18.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Peter Rahmer also recently made the following trade(s):

• On Tuesday, April 28th, Peter Rahmer sold 753 shares of Relay Therapeutics stock. The stock was sold at an average price of $14.79, for a total value of $11,136.87.

Relay Therapeutics Price Performance

Shares of RLAY stock opened at $18.65 on Friday. The stock’s fifty day simple moving average is $14.74 and its 200 day simple moving average is $11.55. The firm has a market cap of $3.57 billion, a price-to-earnings ratio of -11.88 and a beta of 1.67. Relay Therapeutics, Inc. has a one year low of $3.03 and a one year high of $19.93.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $5.58 million. On average, research analysts anticipate that Relay Therapeutics, Inc. will post -1.55 earnings per share for the current year.

Institutional Trading of Relay Therapeutics

Large investors have recently made changes to their positions in the business. Torren Management LLC acquired a new stake in shares of Relay Therapeutics in the fourth quarter valued at $30,000. KBC Group NV acquired a new position in Relay Therapeutics during the 1st quarter worth about $34,000. Smartleaf Asset Management LLC lifted its position in Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock worth $37,000 after buying an additional 3,287 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Relay Therapeutics during the 4th quarter worth about $46,000. Finally, Captrust Financial Advisors bought a new stake in Relay Therapeutics during the 2nd quarter worth about $49,000. Institutional investors own 96.98% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. The Goldman Sachs Group increased their target price on shares of Relay Therapeutics from $13.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. UBS Group set a $26.00 price target on shares of Relay Therapeutics in a research report on Tuesday, May 19th. Barclays boosted their price target on shares of Relay Therapeutics from $21.00 to $27.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Wednesday, April 8th. Finally, JonesTrading raised shares of Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $23.30.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.